You are here: Agreements > Confidentiality Agreement > MEDIVATION ENTERS INTO CONFIDENTIALITY AGREEMENTS, INCLUDING WITH SANOFI Sanofi to Terminate its Consent Solicitation Board Committed to Delivering Value and Acting in Stockholders' Best Interests

SITE SEARCH
AGREEMENTS / CONTRACTS
(optional)
(optional)
Try our advanced search >>
CLAUSES Search Contract Clauses >>
Browse Contract Clause Library>>

Medivation Enters Into Confidentiality Agreements, Including With Sanofi Sanofi To Terminate Its Consent Solicitation Board Committed To Delivering Value And Acting In Stockholders' Best Interests

Confidentiality Agreement

Legal Documents
You are currently viewing:

 This Confidentiality Agreement involves

MEDIVATION, INC. | Medivation, Inc

. RealDealDocs™ contains millions of easily searchable legal documents and clauses from top law firms. Search for free - click here.
 

Title: MEDIVATION ENTERS INTO CONFIDENTIALITY AGREEMENTS, INCLUDING WITH SANOFI Sanofi to Terminate its Consent Solicitation Board Committed to Delivering Value and Acting in Stockholders' Best Interests
Date: 7/5/2016
Industry: Biotechnology and Drugs     Law Firm: Wachtell Lipton     Sector: Healthcare

join now
50 of the Top 250 law firms use our Products every day

Exhibit 99.1

MEDIVATION ENTERS INTO CONFIDENTIALITY AGREEMENTS, INCLUDING WITH SANOFI

Sanofi to Terminate its Consent Solicitation

Board Committed to Delivering Value and Acting in Stockholders’ Best Interests

SAN FRANCISCO, CA – July 5, 2016 – Medivation, Inc. (NASDAQ: MDVN) today announced that it has entered into confidentiality agreements with a number of parties that have expressed interest in exploring a potential transaction and demonstrated that interest to the Board of Directors’ satisfaction. Medivation also confirmed that it entered into a confidentiality agreement with Sanofi and that Sanofi agreed to terminate its consent solicitation. Before entering into the confidentiality agreement with Sanofi, Medivation received from Sanofi, and Medivation’s Board of Directors unanimously rejected as not in the best interests of the company and its stockholders, a new unsolicited proposal to acquire Medivation. The proposal, which was conditional upon the execution of a confidentiality agreement and the receipt of information, was for $58.00 per share in cash plus a Contingent Value Right for talazoparib sales representing a potential payment in 2022 of a maximum of $3.00 per share.

The confidentiality agreements include customary six-month standstill provisions, subject to limited early termination events, and Medivation expects to provide each party the opportunity in the near term to review non-public information and meet with Medivation’s management.

Kim Blickenstaff, Chairman of Medivation’s Board of Directors, said, “Medivation has significant scarcity value as one of the only profitable, commercial-stage oncology companies, and management has been successfully executing a strategy that is generating outstanding returns for our stockholders. At the same time, our Board remains committed to objectively considering all avenues that may enhance our ability to deliver superior value. Our decision to enter into these agreements is consistent with our focus on stockholder interests, and will allow interested parties to fully understand the significant value of our XTANDI franchise and the enormous potential of our pipeline, including talazoparib, our promising, potential best-in-class PARP inhibitor.”

Evercore and J.P. Morgan are serving as financial advisors to Medivation, and Wachtell, Lipton, Rosen & Katz and Cooley LLP are acting as legal counsel.

About Medivation, Inc.

Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment


continue to document